U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H22O4
Molecular Weight 302.3649
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MASOPROCOL

SMILES

C[C@@H](CC1=CC=C(O)C(O)=C1)[C@H](C)CC2=CC=C(O)C(O)=C2

InChI

InChIKey=HCZKYJDFEPMADG-TXEJJXNPSA-N
InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+

HIDE SMILES / InChI

Molecular Formula C18H22O4
Molecular Weight 302.3649
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Misoprostol is an antineoplastic drug used to treat skin growths caused by sun exposure. Masoprocol is a novel antineoplastic agent was used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated). Masoprocol was withdrawn from the U.S. market in June 1996. It is not known exactly how Masoprocol works. Studies have shown that masoprocol is a potent 5-lipoxygenase inhibitor and has antiproliferative activity against keratinocytes in tissue culture, but the relationship between this activity and its effectiveness in actinic keratoses is unknown. Masoprocol also inhibits prostaglandins but the significance of this action is not yet known. Symptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing.

Originator

Curator's Comment: Masoprocol was originally developed by Access Pharmaceuticals (now PlasmaTech Biopharmaceuticals)

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACTINEX

Approved Use

Used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated).

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
14.7 μg/mL
50 mg/kg single, intravenous
dose: 50 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MASOPROCOL plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
247.7 μg × min/mL
50 mg/kg single, intravenous
dose: 50 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MASOPROCOL plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
135 min
50 mg/kg single, intravenous
dose: 50 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MASOPROCOL plasma
Mus musculus
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2500 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2500 mg, 1 times / day
Sources:
unhealthy, 48-81 years
Health Status: unhealthy
Age Group: 48-81 years
Sex: M
Sources:
10 % 2 times / day multiple, topical
Dose: 10 %, 2 times / day
Route: topical
Route: multiple
Dose: 10 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
Other AEs: Contact dermatitis...
Other AEs:
Contact dermatitis (4 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Contact dermatitis 4 patients
10 % 2 times / day multiple, topical
Dose: 10 %, 2 times / day
Route: topical
Route: multiple
Dose: 10 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
PubMed

PubMed

TitleDatePubMed
Establishment of a first-order kinetic model of light chain-associated amyloid fibril extension in vitro.
2002-11-19
Concerted regulation of free arachidonic acid and hormone-induced steroid synthesis by acyl-CoA thioesterases and acyl-CoA synthetases in adrenal cells.
2002-11
Regulation of apoptosis through arachidonate cascade in mammalian cells.
2002-10-25
Bradykinin increases permeability by calcium and 5-lipoxygenase in the ECV304/C6 cell culture model of the blood-brain barrier.
2002-10-25
Contribution of different phospholipases and arachidonic acid metabolites in the response of gallbladder smooth muscle to cholecystokinin.
2002-10-01
Investigation of the role of lipoxygenase in bioactivation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung.
2002-10
Effect of nordihydroguaiaretic acid on intracellular Ca(2+) concentrations in hepatocytes.
2002-10
Effect of nordihydroguaiaretic acid on the secretion of lipoprotein lipase.
2002-09-30
Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors.
2002-09-15
Platelet aggregating response to platelet activating factor participates in activation of the 12-lipoxygenase pathway in platelets from rabbits.
2002-09
N-acylethanolamines are metabolized by lipoxygenase and amidohydrolase in competing pathways during cottonseed imbibition.
2002-09
Design, synthesis, and biological evaluation of a cephalosporin-monohydroguaiaretic acid prodrug activated by a monoclonal antibody-beta-lactamase conjugate.
2002-09
[Lipoxygenase inhibitors induce rat hepatocyte apoptosis in primary culture].
2002-08-30
Neurons overexpressing mutant presenilin-1 are more sensitive to apoptosis induced by endoplasmic reticulum-Golgi stress.
2002-08-15
Kinetics of inhibition of leukocyte 12-lipoxygenase by the isoform-specific inhibitor 4-(2-oxapentadeca-4-yne)phenylpropanoic acid.
2002-08-13
Stimulatory effects of adenosine on prolactin secretion in the pituitary gland of the rat.
2002-07
Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase.
2002-06-06
Nordihydroguaiaretic acid-mediated inhibition of ultraviolet B-induced activator protein-1 activation in human keratinocytes.
2002-06
Participation of the arachidonic acid cascade pathway in macrophage binding/uptake of oxidized low density lipoprotein.
2002-06
Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro.
2002-05-31
alpha 2B-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation.
2002-05-31
Effects of brefeldin A and nordihydroguaiaretic acid on endomembrane dynamics and lipid synthesis in plant cells.
2002-05-08
Mechanisms underlying the activation of large conductance Ca2+-activated K+ channels by nordihydroguaiaretic acid.
2002-05
Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro.
2002-05
Involvement of glycogen synthase kinase-3beta and tau phosphorylation in neuronal Golgi disassembly.
2002-05
Effects of cyclooxygenase and lipoxygenase inhibition on basal- and serotonin-induced ion transport in rat colon.
2002-05
Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells.
2002-04-08
[Simultaneous determination of five antioxidants in food by HPLC with fluorescence detection].
2002-04
Comparative quantitative structure toxicity relationships for flavonoids evaluated in isolated rat hepatocytes and HeLa tumor cells.
2002-03-20
Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols.
2002-03-15
Possible implication of Golgi-nucleating function for the centrosome.
2002-03-01
Effects of various reactive oxygen species on the guinea pig trachea and its epithelium.
2002-03
Expression and induction of the stress protein alpha-B-crystallin in vascular endothelial cells.
2002-03
Effect of nordihydroguaiaretic acid on intracellular Ca(2+) concentrations in C6 glioma cells.
2002-03
Effects of inhibitors of the lipo-oxygenase family of enzymes on the store-operated calcium current I(CRAC) in rat basophilic leukaemia cells.
2002-02-15
Tending tender tendons.
2002-02-08
Arachidonic and linoleic acid metabolism in mouse intestinal tissue: evidence for novel lipoxygenase activity.
2002-02-01
Native LDL induces proliferation of human vascular smooth muscle cells via redox-mediated activation of ERK 1/2 mitogen-activated protein kinases.
2002-02
Multiple biological effects of inhibitors of arachidonic acid metabolism on human keratinocytes.
2002-02
5-Lipoxygenase and human pulmonary artery endothelial cell proliferation.
2002-02
Evidence for the involvement of cyclooxygenase activity in the development of cocaine sensitization.
2002-01-29
Differential effect of brefeldin A on the palmitoylation of surfactant protein C proprotein mutants.
2002-01-11
Cytosolic phospholipase A2 and lipoxygenase are involved in cell cycle progression in neuroblastoma cells.
2002-01
The lipoxygenase pathways are involved in LH-stimulated progesterone production in bovine corpus luteum.
2002-01
[Effect of exogenous leukotrienes and lipoxygenase inhibitors on apoptosis and necrosis in cultured rat hepatocytes].
2002
Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues.
2001-12
Nordihydroguaiaretic acid elevates osteoblastic intracellular Ca2+.
2001-12
Progressive apoptosis in chorion laeve trophoblast cells of human fetal membrane tissues during in vitro incubation is suppressed by antioxidative reagents.
2001-12
Lipoxygenase inhibitors inhibit heparin-releasable lipoprotein lipase activity in 3T3-L1 adipocytes and enhance body fat reduction in mice by conjugated linoleic acid.
2001-11-30
Intracellular signaling pathway of FGF-2-modulated corneal endothelial cell migration during wound healing in vitro.
2001-11
Patents

Sample Use Guides

Apply to lesions b.i.d. for 14–28 d
Route of Administration: Topical
Incubation of masoprocol (50 uM) with adipocytes from chow-fed rats significantly inhibited isoproterenol-induced lipolytic activity and HSL activity, associated with a decrease in the ability of isoproterenol to phosphorylate HSL. Masoprocol had no apparent effect on adipose tissue phosphatidylinositol 3-kinase activity, but okadaic acid, a serine/threonine phosphatase inhibitor, blocked the antilipolytic effect of masoprocol.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:32:55 GMT 2025
Edited
by admin
on Mon Mar 31 18:32:55 GMT 2025
Record UNII
7BO8G1BYQU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MASOPROCOL
INN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
NORDIHYDROGUAIARETIC ACID
INCI   MI   WHO-DD  
INCI  
Preferred Name English
INSM18
Common Name English
MESO-4,4'-(2,3-DIMETHYLTETRAMETHYLENE)DIPYROCATECHOL
Common Name English
MASOPROCOL [MART.]
Common Name English
NORDIHYDROGUIARETIC ACID
Common Name English
ACTINEX
Brand Name English
1,2-BENZENEDIOL, 4,4'-(2,3-DIMETHYL-1,4-BUTANEDIYL)BIS-, (R*,S*)-
Common Name English
NSC-4291
Code English
Masoprocol [WHO-DD]
Common Name English
NORDIHYDROGUAIARETIC ACID [MI]
Common Name English
INSM-18
Common Name English
ORISTAR NHGA
Brand Name English
DIHYDRONORGUAIARETIC ACID
Common Name English
MESO-NDGA
Code English
NDGA
Common Name English
CHX-100
Code English
NSC-682984
Code English
MASOPROCOL [VANDF]
Common Name English
Nordihydroguaiaretic Acid [WHO-DD]
Common Name English
MASOPROCOL [USAN]
Common Name English
4-((2R,3S)-4-(3,4-DIHYDROXYPHENYL)-2,3-DIMETHYLBUTYL)BENZENE-1,2-DIOL
Systematic Name English
masoprocol [INN]
Common Name English
MESO-NORDIHYDROGUAIARETIC ACID
Common Name English
NORDIHYDROGUAIARETATE
Common Name English
1,2-BENZENEDIOL, 4,4'-((2R,3S)-2,3-DIMETHYL-1,4-BUTANEDIYL)BIS-, REL-
Systematic Name English
MASOPROCOL [ORANGE BOOK]
Common Name English
DINORGUAIARETIC ACID, DIHYDRO-
Common Name English
1,2-BENZENEDIOL, 4,4'-(2,3-DIMETHYL-1,4-BUTANEDIYL)BIS-
Systematic Name English
1,4-BIS(3,4-DIHYDROXYPHENYL)-2,3-DIMETHYLBUTANE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C275
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
NCI_THESAURUS C1322
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
WHO-VATC QL01XX10
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
CFR 21 CFR 189.165
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
WHO-ATC L01XX10
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
Code System Code Type Description
USAN
BB-4
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
WIKIPEDIA
NORDIHYDROGUAIARETIC ACID
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
RXCUI
227239
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY RxNorm
EVMPD
SUB08652MIG
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
CAS
500-38-9
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
NON-SPECIFIC STEREOCHEMISTRY
IUPHAR
4265
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
ECHA (EC/EINECS)
207-903-0
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
ALTERNATIVE
CAS
27686-84-6
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
NSC
682984
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
ECHA (EC/EINECS)
248-606-6
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
MESH
D009637
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
NCI_THESAURUS
C701
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
PUBCHEM
71398
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
CHEBI
7625
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
NSC
4291
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
FDA UNII
7BO8G1BYQU
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
INN
6615
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
RXCUI
1860612
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
ALTERNATIVE
MERCK INDEX
m8052
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY Merck Index
CHEBI
73468
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
DRUG CENTRAL
1637
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
DAILYMED
7BO8G1BYQU
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
ChEMBL
CHEMBL3545025
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
SMS_ID
100000081745
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
EPA CompTox
DTXSID5045178
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
DRUG BANK
DB00179
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
ChEMBL
CHEMBL52
Created by admin on Mon Mar 31 18:32:55 GMT 2025 , Edited by admin on Mon Mar 31 18:32:55 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY